Elsevier

Cancer Treatment Reviews

Volume 59, September 2017, Pages 22-32
Cancer Treatment Reviews

Anti-Tumour Treatment
Long-term management of patients with hormone receptor-positive metastatic breast cancer: Concepts for sequential and combination endocrine-based therapies

https://doi.org/10.1016/j.ctrv.2017.06.004Get rights and content
Under a Creative Commons license
open access

Highlights

  • Sequential ET-based therapy can extend PFS and OS without resorting to chemotherapy.

  • Molecular mechanisms have stimulated research of targeted agents and combinations.

  • Older agents and approaches are being studied due to emerging knowledge.

  • Ongoing research is defining populations likely to benefit from specific therapy.

  • Molecular and genetic profiling is expected to improve care for patients with MBC.

Abstract

Treatment options for hormone receptor-positive (HR-positive) metastatic breast cancer (MBC) continue to increase in parallel with expanding knowledge about the complex biology of breast cancer subtypes and resistance mechanisms to endocrine therapy. For patients with HR-positive MBC, there are now an unprecedented number of endocrine-based treatment options that can improve long-term outcomes, while preserving or optimizing quality of life, and that can be used before selecting more cytotoxic chemotherapeutic regimens. In addition to antiestrogens, steroidal and nonsteroidal aromatase inhibitors, the selective estrogen-receptor degrader, fulvestrant, and new endocrine-based combinations provide significant and clinically meaningful improvements in outcomes in the first line setting and beyond. Also, new clinical scenarios and indications for monotherapy endocrine and targeted therapies continue to be explored. Patients have several therapeutic options when their disease progresses or becomes resistant, although the optimal sequencing of these therapies remains unclear. Ongoing research in the resistant/refractory setting is anticipated to continue improving the outlook for these patients. This review will discuss current and investigational approaches to sequential single-agent endocrine and endocrine-based combination therapy for the long-term management of patients with HR-positive, human epidermal growth factor receptor 2-negative MBC.

Keywords

Breast neoplasms
Antineoplastic agents
Hormonal biological products
Biological markers
Disease-free survival

Cited by (0)